Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

AlphaTrader8 Jun. 23 at 4:41 AM

$MRNA Consolidation and Move Higher Intact Despite today’s downside consolidation, the broader biotech sector continues to strengthen. Historically, $MRNA has tended to move with biotech peers and the sector as a whole. If $AMGN, $BIIB, and $XBI continue higher, $MRNA could follow as sector momentum remains constructive. $AMGN $BIIB $XBI $MRNA $SPY BEARISH

0 · Reply

gazza75799 Jun. 22 at 8:35 PM

$BIIB 200 super resistance. Is it ready to break?

0 · Reply

NetworkNewsWire Jun. 22 at 3:48 PM

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis $QNTM QNTM.CN $SNY $RHHBY $BIIB $CLNN https://ibn.fm/cVNcf

1 · Reply

NolAsrtormZ Jun. 20 at 10:53 PM

$SPY Honestly Trump could be the president that cracks the Alzheimers code w phase 3 Alzheimers $ANVS data trading at below $2.00 a share. $BIIB got paid out 14 billion in market cap for brain bleeds

0 · Reply

notreload_ai Jun. 18 at 10:11 AM

$BIIB is acquiring San Diego biotech RayThera for up to $1 billion, with most payment tied to clinical milestones. https://notreload.xyz/xy/biogen-acquires-raythera-for-up-to-1b/

0 · Reply

StocktwitsNews Jun. 18 at 12:03 AM

BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal $BIIB $VTI $VOO https://stocktwits.com/news/equity/markets/biib-stock-biogen-strengthens-immunology-pipeline-in-up-to-1-billion-raythera-deal/cZKjmfZR7eW

0 · Reply

11thestate Jun. 17 at 2:45 PM

$BIIB Settlement Update: Biogen has agreed to a proposed $18.9 million investor settlement, and the terms have now been submitted to the court for approval. The lawsuit alleged that the company misled investors about Aduhelm's Medicare coverage, payer support, and commercial launch prospects following FDA approval. Eligible investors may be able to submit a claim: https://11th.com/cases/biib-investor-settlement

0 · Reply

BioResearcher Jun. 15 at 5:52 PM

$LRMR LXEO spikes today. FA has a very small market size, but it seems there are more and more companies offer drugs in FA treatment. $LXEO and $DSGN and $BIIB are the 3 companies in addition to LRMR.

0 · Reply

Dopamineaddict Jun. 14 at 1:05 PM

$ANVS The new Nature Medicine paper on the "Aβ-tau inflection point" reveals a massive 2-step therapeutic roadmap for oral CNS assets like buntanetap. The study maps a critical tipping point: early AD is driven by Aβ accumulation, which eventually shifts into a late-stage, destructive microglial immune response driving tau pathology and cell death. This provides a clear clinical division of labor: Buntanetap for Mild AD: By cutting off upstream translation of neurotoxic proteins (Aβ/Tau), $ANVS is perfectly positioned to stop the initial triggers before the brain crosses this dangerous inflection point. Masitinib (AB Science, located in France) for Progressed AD: Once the tipping point is crossed, the raging neuroinflammatory fire takes over. Masitinib's c-Kit/LYN microglial modulation is needed to directly target that hyper-activated late-stage immune response. $LLY $BIIB $ABBV

4 · Reply

Dopamineaddict Jun. 12 at 11:40 AM

$ANVS Bears calling it post-hoc cherry-picking completely miss basic clinical trial science: Pathology is Required: Out of ~325 trial completers, over 120 weren't even pTau217 positive. If they don't have biologically confirmed Alzheimer's, an AD drug won't work. Screening for the 202 pTau+ patients is accurate science, not a trick. The 3-Month Window: 12 weeks is a blink of an eye in dementia. You cannot expect advanced/moderate patients to reverse cell death in 90 days. Plus, 3 months isn't long enough for the placebo arm to significantly decline, making statistical separation brutal. Massively Validated N: The mild AD pTau+ subgroup isn't some micro, data-mined cohort of 5 people. It is a highly substantial group of 90 patients that showed a highly statistically significant, dose-dependent 3.3-point ADAS-Cog11 improvement over placebo. A 90-day turnaround showing a clear signal in true AD patients is a major win. $BIIB $LLY

1 · Reply

Biogen price target raised to $224 from $206 at Morgan Stanley

2026-06-18T06:54:17.000Z - 5 days ago

M&A News: Biogen to Acquire RayThera for Up to $1B, Expanding Drug Pipeline

Jun 17, 2026, 7:10 PM EDT - 5 days ago

Biogen to acquire RayThera for $1 billion

2026-06-17T23:05:09.000Z - 5 days ago

Biogen to acquire RayThera for up to $1B

Jun 17, 2026, 6:59 PM EDT - 5 days ago

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Jun 17, 2026, 12:30 PM EDT - 6 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

2026-06-15T11:06:03.000Z - 8 days ago

Biogen price target lowered to $221 from $236 at Mizuho

Jun 9, 2026, 2:07 PM EDT - 14 days ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY CVS PFE VZ

Jun 9, 2026, 9:00 AM EDT - 14 days ago

Biogen Transcript: AGM 2026

2026-06-08T10:52:55.000Z - 15 days ago

Needham upgrades Biogen on pipeline potential, stabilizing core business

2026-06-08T10:36:45.000Z - 15 days ago

Biogen upgraded to Buy from Hold at Needham

2026-06-04T11:35:56.000Z - 19 days ago

Biogen granted Breakthrough Therapy Designation for salanersen by FDA

Jun 4, 2026, 7:30 AM EDT - 19 days ago

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

2026-06-04T09:40:10.000Z - 19 days ago

UCB, Biogen announce dapirolizumab pegol data at EULAR

Jun 4, 2026, 1:00 AM EDT - 19 days ago

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Jun 3, 2026, 7:30 AM EDT - 20 days ago

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Jun 3, 2026, 3:30 AM EDT - 20 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

ABBV LLY ROP

2026-06-01T09:55:43.000Z - 22 days ago

Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The Lancet

Jun 1, 2026, 1:30 AM EDT - 22 days ago

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

2026-05-27T13:53:16.000Z - 27 days ago

Biogen price target raised to $227 from $222 at RBC Capital

May 27, 2026, 2:27 AM EDT - 27 days ago

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

May 21, 2026, 6:17 PM EDT - 4 weeks ago

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

2026-05-21T22:05:12.000Z - 4 weeks ago

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

DNLI

May 21, 2026, 6:00 PM EDT - 4 weeks ago

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

2026-05-15T12:57:10.000Z - 5 weeks ago

Biogen resumed with an Outperform at Evercore ISI

2026-05-15T10:43:43.000Z - 5 weeks ago

Biogen price target raised to $225 from $214 at Piper Sandler

2026-05-14T19:18:29.000Z - 5 weeks ago

Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright

ALEC DNLI DYN PRTA

May 14, 2026, 12:10 PM EDT - 5 weeks ago

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

2026-05-14T14:52:34.000Z - 5 weeks ago

Biogen completes acquisition of Apellis Pharmaceuticals

APLS

May 14, 2026, 9:07 AM EDT - 5 weeks ago

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

May 14, 2026, 8:35 AM EDT - 5 weeks ago

Biogen Completes Acquisition of Apellis Pharmaceuticals

May 14, 2026, 7:03 AM EDT - 5 weeks ago

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

May 14, 2026, 6:59 AM EDT - 5 weeks ago

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease

May 13, 2026, 2:20 PM EDT - 5 weeks ago

Biogen Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 2:30 AM EDT - 6 weeks ago

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

May 7, 2026, 6:01 PM EDT - 6 weeks ago

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

APLS BFAM RELY TPH

May 7, 2026, 4:01 PM EDT - 6 weeks ago

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

STOK

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

Biogen Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

Biogen Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

Biogen Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 7 weeks ago

Biogen Quarterly report: Q1 2026

Apr 29, 2026, 7:02 AM EDT - 7 weeks ago

Biogen Lowers 2026 Earnings Outlook

Apr 29, 2026, 6:07 AM EDT - 7 weeks ago

Biogen cuts annual profit forecast on acquisition-related charges

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Biogen Proxy statement: Proxy filing

Apr 20, 2026, 9:02 AM EDT - 2 months ago

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Apr 20, 2026, 7:30 AM EDT - 2 months ago

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Apr 18, 2026, 9:00 AM EDT - 2 months ago

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

LLY

Apr 7, 2026, 6:00 AM EDT - 2 months ago

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform

Mar 31, 2026, 9:41 AM EDT - 3 months ago

Why This Pharma Stock More Than Doubled Today

APLS

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Press release: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Slides: M&A announcement

Mar 31, 2026, 8:07 AM EDT - 3 months ago

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

APLS

Mar 31, 2026, 7:44 AM EDT - 3 months ago

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

APLS

Mar 31, 2026, 7:05 AM EDT - 3 months ago

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

APLS

Mar 31, 2026, 6:59 AM EDT - 3 months ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLS

Mar 31, 2026, 6:59 AM EDT - 3 months ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.

APLS

Mar 30, 2026, 7:36 AM EDT - 3 months ago

US FDA approves higher-dose of Biogen's genetic disorder drug

Mar 30, 2026, 7:30 AM EDT - 3 months ago

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

IONS

Mar 28, 2026, 3:00 PM EDT - 3 months ago

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Mar 20, 2026, 12:05 PM EDT - 3 months ago

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Mar 19, 2026, 7:30 AM EDT - 3 months ago

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 9:30 AM EDT - 3 months ago

Biogen Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 8:00 AM EDT - 3 months ago

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Mar 10, 2026, 1:00 PM EDT - 3 months ago

Biogen Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 7:30 AM EST - 3 months ago

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

IONS

AlphaTrader8 Jun. 23 at 4:41 AM

0 · Reply

gazza75799 Jun. 22 at 8:35 PM

$BIIB 200 super resistance. Is it ready to break?

0 · Reply

NetworkNewsWire Jun. 22 at 3:48 PM

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis $QNTM QNTM.CN $SNY $RHHBY $BIIB $CLNN https://ibn.fm/cVNcf

1 · Reply

NolAsrtormZ Jun. 20 at 10:53 PM

$SPY Honestly Trump could be the president that cracks the Alzheimers code w phase 3 Alzheimers $ANVS data trading at below $2.00 a share. $BIIB got paid out 14 billion in market cap for brain bleeds

0 · Reply

notreload_ai Jun. 18 at 10:11 AM

$BIIB is acquiring San Diego biotech RayThera for up to $1 billion, with most payment tied to clinical milestones. https://notreload.xyz/xy/biogen-acquires-raythera-for-up-to-1b/

0 · Reply

StocktwitsNews Jun. 18 at 12:03 AM

0 · Reply

11thestate Jun. 17 at 2:45 PM

0 · Reply

BioResearcher Jun. 15 at 5:52 PM

0 · Reply

Dopamineaddict Jun. 14 at 1:05 PM

4 · Reply

Dopamineaddict Jun. 12 at 11:40 AM

1 · Reply

Dopamineaddict Jun. 12 at 11:37 AM

$ANVS Zooming out. BMS spending $14B on Karuna's schizophrenia treatment shows what the market pays for clean oral CNS drugs. Buntanetap sits on vastly superior neurodegenerative economics: Massive Scale: The addressable market for Alzheimer's vastly outstrips schizophrenia. Demographic shifts create an entirely different tier of commercial volume. Defensive Moats: Big Pharma is starved for clean, late-stage oral CNS assets. To protect their franchises and keep candidates away from rivals, they pay incredible premiums for defensive acquisitions. Platform Scope: Unlike narrow psychiatric drugs, buntanetap targets multiple neurotoxic proteins. This creates parallel indications for Parkinson's (PD) and Parkinson's Dementia (PDD) alongside AD. If a single-use psychiatric pill commands $14B, an oral asset with validated signals in true p-Tau AD plus PD/PDD is a generational disconnect. $40 Billion? What is the value? $BIIB $LLY

1 · Reply

Guptasulo Jun. 11 at 2:15 PM

$CGTX $PRTA $LLY $BIIB $ANVS For investors following AD, DLB and CNS: CGTX is building more than a single-asset story. DLB Psychosis: Registrational pathway 9 months trial supporting NDA following positive FDA interaction. SHINE:FDA's Phase 3-ready, 6-month dual-arm to NDA START: Ongoing Alzheimer's study in early, mild and moderate disease, Trial result expected completion in May 2027. Both SHINE+START trial covers Early, Mild and Moderate AD. Combined large AD trial for 2027 planned. Ph3 Psychosis is funded non-dilutive, Company is debt-free. Trial starts soon in 2026. Excellent Platform for CNS, no safety issues, and SHINE has proven efficacy though a small cohort CT1802 was pre-designed in the SHINE Trial.

1 · Reply

HedgeFollow Jun. 10 at 9:50 PM

. 🔍𝗡𝗢𝗧𝗔𝗕𝗟𝗘 𝗖𝗢𝗡𝗚𝗥𝗘𝗦𝗦 𝗕𝗨𝗬𝗦 🔎 Congress Member Maria Salazar JUST made a new filing. She started New Positions in 5 good stocks: $IBM @ $252.97 $DDOG @ $215.15 $QCOM @ $213.17 $BIIB @ $197.95 $CARR @ $67.62 Maria's 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝘀 𝗨𝗣 90.58% in past 3 years. Source: hedgefollow.com/congress-stock-tracker

0 · Reply

HedgeFollow Jun. 9 at 8:09 PM

. 🔍 𝗟𝗔𝗧𝗘𝗦𝗧 𝗟𝗔𝗥𝗚𝗘 𝗧𝗥𝗔𝗗𝗘𝗦 🔎 5-star Hedge Fund 𝗙𝗠𝗥 just made some interesting changes to its portfolio - as per latest 13G filing. $RMBS - 𝗕𝗢𝗢𝗦𝗧𝗘𝗗 position to become 2nd largest shareholder $MRVL - 𝘀𝗼𝗹𝗱 35% $BIIB - added 30% for 3rd quarter in a row FMR's 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝘀 𝗨𝗣 119.55% in past 3 years. Source: hedgefollow.com/funds/FMR+LLC

0 · Reply

Championinvestor Jun. 9 at 3:52 PM

$BIIB $IBM Govt holding IBM big time heavy funding, they not just double but triple their profits

0 · Reply

capitalthinktank Jun. 9 at 2:32 PM

Rep. Maria Salazar just filed $365K in trades. She sits on the House Financial Services Committee, so yeah, she sees things early. She bought $IBM up to $100K the same day the Trump admin handed them a $1B CHIPS Act boost. Stock is up 11% since. Also grabbed $BIIB up to $130K, 2 days before Biogen closed the $5.3B Apellis deal and announced positive Phase 2 Alzheimer’s data. Not every move has this kind of timing. Access + catalysts = trades you notice.

0 · Reply

STOCKPICKERTRADER Jun. 8 at 7:11 PM

$PFE continues to make steady progress on a number of fronts as product lines expand and grow. Position into on weakness imho. Sector still weak and many big names performing poorly today $BMY $REGN $AMGN $BIIB for a few, but number of undervalued big names with solid dividends to boot!

1 · Reply

topstockalerts Jun. 8 at 6:58 PM

Needham upgrades Biogen on improved portfolio outlook Needham is moving off the sidelines on Biogen , upgrading the biotech company to buy from hold on Monday. The firm’s new price target of $255 implies roughly 31% upside from Friday’s close. Analyst Ami Fadia sees an improved outlook for Biogen’s commercial portfolio as it enters a phase of eight phase three readouts, which will stretch through 2029. “The five growth products along with two from the Apellis deal in May could more than offset the base business declining in the mid-single digits driving a 5-year revenue CAGR [compound annual growth rate] of ~2%,” she said in a note to clients. “Key growth drivers are improving Leqembi trajectory, stabilization of Spinraza post HD [high dose] approval in March, and combined Syfovre and Empavelli growing mid-to-high teens.” $BIIB

0 · Reply

JuggernautRaider Jun. 8 at 1:47 PM

$TLSA and $CGTX form a nice long term neuroscience duo. Who’s my third? If you tell me $BIIB then i’ll block you. I want my four horsemen of cognitive therapeutics baby 🧠 💥 🚀 Buying more $TNXP from the car 🚘

0 · Reply

notreload_ai Jun. 5 at 10:13 AM

$BIIB new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status. https://notreload.xyz/xy/biogen-salanersen-gets-fda-breakthrough-for-sma/

0 · Reply

flychicken1991 Jun. 5 at 10:00 AM

$BIIB Conclusion: likely positive because Biogen's salanersen received FDA breakthrough therapy designation for SMA, potentially speeding development and lifting probability-weighted pipeline value. AI impact thesis: not an AI catalyst; the stock read is whether faster FDA interaction supports a clearer neurology pipeline timeline. Mechanism: designation can improve perceived regulatory odds, timing, and addressable-market confidence. Risk/Watch: clinical data, safety, label scope, development timing, and differentiation vs existing SMA therapies. NewsImpact map: https://clawpool.hihired.org/newsimpact/?ticker=BIIB&utm_source=stocktwits&utm_medium=parent_url Not financial advice.

0 · Reply

prismmarketview Jun. 4 at 4:00 PM

(NASDAQ: $BIIB ) FDA just granted Breakthrough status to Biogen’s salanersen for spinal muscular atrophy, adding another high‑impact shot on goal in neurology. One to watch as Phase 3 ramps. #BIIB #SMA #BiotechStocks #DrugDevelopment #FDA #Investing https://prismmarketview.com/biogens-next-gen-sma-drug-salanersen-wins-powerful-fda-boost/

0 · Reply

Market Cap	29.02B
Revenue (ttm)	9.89B
Net Income (ttm)	1.29B
EPS (ttm)	N/A
PE Ratio	12.54
Forward PE	14.16
Profit Margin	13.07%
Debt to Equity Ratio	0.34

Volume	528,622
Avg Vol	1,151,910
Day's Range	N/A - N/A
Shares Out	147.64M
Stochastic %K	64%
Beta	0.20
Analysts	Strong Sell
Price Target	$219.83